Events

June 18-20, 2019 – Park Central Hotel, San Francisco, CA
Safety and Efficacy of TCR-mimic Technology in Hematologic and Solid Tumors

May 13-17, 2019 – Encore Hotel, Las Vegas, NV
Antibody-TCR ARTEMIS” T-cell Therapy for Solid Tumors & Hematological Malignancies

April 16-17, 2019 – InterContinental Shanghai Ruijin Hotel, Shanghai, China
Antibody-TCR (AbTCR) T-cell Therapy for Solid and Hematological Malignancies

April 5, 2019 – Boston Harbor Hotel, Boston, MA
Antibody-TCR (AbTCR) T-cell Therapy for Solid and Hematological Malignancies

March 20-21, 2019 – Apella Event Space Alexandria Center, New York, NY
ARTEMIS” Antibody-TCR (AbTCR) T-cell Therapy for Solid and Hematological Malignancies

March 14-15, 2019 – Zuckerman Research Center, New York, NY
Development of ARTEMIS” Antibody-TCR (AbTCR) Expressing T Cells Against Solid and Hematological Malignancies with the Potential to Eliminate CRS Risks

March 11-13, 2019 – Boston Marriott Copley Place, Boston, MA
A Novel T-Cell Engineering Technology (ARTEMIS”) for Strong Clinical Efficacy while Mitigating CRS/Neurotoxicity

September 4-7, 2018 – Boston, MA
Overcoming Safety Challenges of Genetically Engineered T-Cell Therapy for the Treatment of Cancer

June 1-5, 2018 – McCormick Place, Chicago, IL
ET190L1-ARTEMIS” T cell therapy leads to complete remission of relapsed and refractory (r/r) B-cell lymphoma with no cytokine release syndrome in the first-in-human clinical study

April 14-18, 2018 – McCormick Place North/South, Chicago, IL
Anti-CD19 ARTEMIS” T cells prevent excessive inflammatory cytokine release, including IL-6, in a co-culture model of CRS